乳腺癌合并自身免疫性或肿瘤相关性肌炎患者的放疗:肿瘤获益与免疫风险的平衡
该结构式叙述性综述检索PubMed与Scopus至2026年3月,定性综合有限且异质的文献,探讨乳腺癌放疗与自身免疫性肌炎的临床交叉问题。文章指出放疗在评估疾病活动度、多学科评估与适形计划前提下并非自动禁忌,强调结构化鉴别诊断而非一概回避。
要点
- 放疗期间肌肉症状需鉴别自身免疫性、副肿瘤性、放射性、纤维化相关或回忆性肌炎。
- MRI是模式化评估最有价值的影像手段,FDG PET-CT与超声在部分病例中提供补充。
- 在评估疾病活动度、多学科评估与适形计划前提下,放疗并非自动禁忌证。
核心结论
- 乳腺癌合并自身免疫性或肿瘤相关性肌炎患者接受放疗需结构化鉴别诊断,而非一概回避。
- 在考虑疾病活动度、多学科评估与适形计划后,放疗不构成自动禁忌证。
研究设计与样本
- 结构式叙述性综述,检索PubMed与Scopus自建库至2026年3月。
- 因文献有限且异质,证据采用定性综合。
主要发现
- 皮肌炎是与恶性肿瘤关联最强的特发性炎症性肌病,乳腺癌是肿瘤相关性肌炎中最常报告的实体瘤之一,尤其见于抗TIF1γ和抗NXP2阳性亚组。
- 乳腺癌治疗期间的肌肉症状可能反映自身免疫性、副肿瘤性、放射性、纤维化相关或回忆性肌炎。
- MRI是模式化评估最有信息量的手段,FDG PET-CT与超声在部分病例中提供补充价值。
- 直接疾病特异性证据稀少,主要来自回顾性系列、混合结缔组织病队列、放射生物学研究与病例报告。
关键数值与推荐
- 诊断评估应整合症状出现时间、照射野分布、影像学、血清学、全身特征与治疗顺序。
- 后续研究应细化风险分层、肌肉特异性剂量约束以及区分放射性、自身免疫性与副肿瘤性肌炎的生物标志物。
临床怎么用
- 对乳腺癌合并肌炎患者,放疗前应多学科评估疾病活动度并制定适形计划。
- 治疗期间出现肌肉症状时,按时间、照射野分布、影像、血清学与全身特征进行结构化鉴别。
- 优先使用MRI进行模式化评估,必要时辅以FDG PET-CT或超声。
局限性
- 直接疾病特异性证据稀疏,主要来自回顾性系列、混合结缔组织病队列、放射生物学研究与病例报告。
- 文献有限且异质,证据仅能定性综合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast cancer radiotherapy and autoimmune myositis intersect in a clinically complex setting in which paraneoplastic disease, pre-existing inflammatory myopathy, and radiation-related muscle injury may overlap. Dermatomyositis is the idiopathic inflammatory myopathy most strongly associated with malignancy, and breast cancer is one of the solid tumours most frequently reported in cancer-associated myositis, particularly in anti-TIF1γ- and anti-NXP2-positive subsets. METHODS: A structured narrative review of PubMed and Scopus was performed from database inception to March 2026. Evidence was synthesised qualitatively owing to limited and heterogeneous literature. RESULTS: Muscle symptoms during breast cancer treatment may reflect autoimmune, paraneoplastic, radiation-induced, fibrosis-related, or recall myositis. MRI is the most informative modality for pattern-based assessment, with FDG PET-CT and ultrasound providing complementary value in selected cases. Although direct disease-specific evidence is sparse and derives largely from retrospective series, mixed connective tissue disease cohorts, radiobiological studies, and case reports, radiotherapy does not appear to represent an automatic contraindication when disease activity, multidisciplinary evaluation, and conformal planning are taken into account. CONCLUSIONS: Breast cancer radiotherapy in patients with autoimmune or cancer-associated myositis requires structured differential diagnosis rather than categorical avoidance. Diagnostic assessment should integrate timing, field distribution, imaging, serology, systemic features, and treatment sequence. Further studies should refine risk stratification, muscle-specific dose constraints, and biomarkers distinguishing radiation-related from autoimmune or paraneoplastic myositis.
引用
- Falivene S, Mercogliano S, Bertolini N, et al. Breast cancer radiotherapy in patients with autoimmune or cancer-associated myositis: balancing oncological benefit and immune-mediated risk. Radiat Oncol. 2026. PMID: 42464399. doi:10.1186/s13014-026-02894-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。